Regulatory requirements and labeling of commercially available prescription (oral) medicines in Sri Lanka: there is room for improvement

Show simple item record

dc.contributor.author Jayasinghe, Manori
dc.contributor.author Srilal, Thotawaththage Loshadhi Indunika
dc.contributor.author Prasadi, Deweni Guruge Pathmila
dc.contributor.author Madushika, Wickramasinghe Senanayakege Sachini
dc.contributor.author Silva, Samanda Marakkala Dileka Udyani
dc.contributor.author Subasinghe, Sewwandi
dc.date.accessioned 2023-01-10T05:33:20Z
dc.date.available 2023-01-10T05:33:20Z
dc.date.issued 2022-03-01
dc.identifier.citation Jayasinghe, M., Srilal, T.L.I., Prasadi, D.G.P. et al. Regulatory requirements and labeling of commercially available prescription (oral) medicines in Sri Lanka: there is room for improvement. J of Pharm Policy and Pract 15, 13 (2022). https://doi.org/10.1186/s40545-022-00409-z en_US
dc.identifier.issn 2052-3211
dc.identifier.uri http://ir.lib.ruh.ac.lk/xmlui/handle/iruor/10126
dc.description.abstract Background: The consistency and the quality of medicine labels are sought through the regulatory frameworks. This study aims at investigating the secondary labels of medicines based on the labeling regulations and guidelines issued by the National Medicines Regulatory Authority (NMRA), Sri Lanka. Methods: A descriptive cross-sectional study was conducted on 53 commonly used prescription-only oral medicines selected using the price regulations published for most commonly used drugs. High-resolution images of 216 brands/ branded generics/generic products’ secondary labels were collected in April 2021 from six community pharmacies in six districts chosen as a convenience sample. Each label was manually assessed using a checklist prepared based on the regulatory requirements by four trained investigators. The status of registration of each product was assessed using the NMRA website. Descriptive statistics were performed. Results: There was a variation observed in labeling regulations and information present on packages. Among the 216 products evaluated, only 148 (68%) products appeared as registered medicines on the NMRA website, and 2.3% of medicines fulflled all stipulated labeling parameters set out by the NMRA, 3% of products abided by the general labeling requirements, and 76% of the products complied with labeling requirements for API. Major defciencies were observed in the presentation of registration numbers and the details of the local agent, which were unaccounted for in 210 (97%) and 131 (61%) products, respectively. The highest consistency (100%) of information was noted with the dosage form, date of manufacture, date of expiry, and batch numbers. Among the restricted information, attractive pictures (2%), web addresses (6%), and over-stickers (34%) were found. Conclusions: The results highlighted a gap between regulatory requirements and practice in medicine labeling information. Regular post-market examination of medicinal labels is highly advised in a country that relies largely on imports. Similarly, careful adherence to the labeling regulations is required. Furthermore, suppliers and local agentsshould be held accountable for ensuring accurate medicine labeling through increased awareness, education, and sanctions. en_US
dc.language.iso en en_US
dc.publisher BMC en_US
dc.subject Policy en_US
dc.subject Labeling of drugs en_US
dc.subject Regulations en_US
dc.subject National Medicines Regulatory Authority en_US
dc.subject NMRA en_US
dc.subject Medication errors en_US
dc.subject Safe use of medicines en_US
dc.subject Medicine label information en_US
dc.subject Medicine packaging en_US
dc.title Regulatory requirements and labeling of commercially available prescription (oral) medicines in Sri Lanka: there is room for improvement en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account